Medscape: Cannabis drug promising for seizures linked to tuberous sclerosis
UC epilepsy expert weighs in on use of cannabis and CBD oil for seizures
An oral formulation of highly purified cannabidiol, or CBD, reduces seizures associated with tuberous sclerosis complex by more than one third, results of a phase 3 multisite randomized trial show.
A rare genetic disorder, TSC is characterized by benign tumors that develop in many parts of the body, including the brain, where they can trigger seizures. Seizures in young children, which manifest as repetitive spasm of the head and legs, are often the presenting symptom of the disease.
Dr. Michael Privitera, professor at UC, UC Health physician and director of the Epilepsy Center at the University of Cincinnati Gardner Neuroscience Institute, said the study "is important because it provides evidence from a rigorous randomized controlled trial that broadens the uses of cannabidiol in epilepsy."
Tags
Related Stories
ServiceNow Vancouver upgrade coming Friday, April. 26
April 17, 2024
The IT Service Portal and Knowledge Base may be intermittently unavailable from 11:45p.m., Friday, April 26, until 4 a.m., Saturday, April 27, during a planned ServiceNow upgrade.
Medscape: Skin adverse events rare after immunotherapy to treat...
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
UC researchers develop new CPAP device
April 17, 2024
Researchers at the University of Cincinnati are developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.